D
David D. Eisenstat
Researcher at University of Alberta
Publications - 117
Citations - 6781
David D. Eisenstat is an academic researcher from University of Alberta. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 34, co-authored 97 publications receiving 5917 citations. Previous affiliations of David D. Eisenstat include Boston Children's Hospital & Netherlands Institute for Neuroscience.
Papers
More filters
Journal ArticleDOI
Interneuron Migration from Basal Forebrain to Neocortex: Dependence on Dlx Genes
TL;DR: In this paper, the number of GABA-expressing cells in neocortical slices is reduced by separating the neocortex from the subcortical telencephalon, and mice lacking the homeodomain proteins DLX-1/DLX-2 show no detectable cell migration from the cell to the brain.
Journal ArticleDOI
Mutations of the homeobox genes dlx-1 and dlx-2 disrupt the striatal subventricular zone and differentiation of late born striatal neurons
Stewart A. Anderson,Mengsheng Qiu,Alessandro Bulfone,David D. Eisenstat,Juanito J. Meneses,Roger A. Pedersen,John L.R. Rubenstein +6 more
TL;DR: It is reported that mice lacking both DlX-1 and Dlx-2 have a time-dependent block in striatal differentiation, which indicates abnormalities in the development of the striatal subventricular zone and in the differentiation of striatal matrix neurons.
Journal ArticleDOI
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James Perry,Karl Belanger,Warren P. Mason,Dorcas Fulton,Petr Kavan,Jacob C. Easaw,Claude Shields,Sarah Kirby,David R. Macdonald,David D. Eisenstat,Brian Thiessen,Peter A. Forsyth,Jean-François Pouliot +12 more
TL;DR: Rechallenge with continuous dose-intense TMZ 50 mg/m(2)/d is a valuable therapeutic option for patients with recurrent GBM and patients who experience progression during the first six cycles of conventional adjuvant TMZ therapy or after a treatment-free interval get the most benefit from therapy.
Journal ArticleDOI
DLX-1, DLX-2, and DLX-5 expression define distinct stages of basal forebrain differentiation.
David D. Eisenstat,Jen Kuei Liu,Marina Mione,Weimin Zhong,Guoying Yu,Stewart A. Anderson,Ingrid Ghattas,Luis Puelles,John L.R. Rubenstein +8 more
TL;DR: Analysis of the distribution of Dlx‐1 and DLX‐2 in M‐phase cells suggests that these proteins are distributed symmetrically to daughter cells during mitosis, and it is proposed thatDLX‐negative cells in the ventricular zone are specified progressively to become DLx‐2‐expressing cells during neurogenesis.
Journal ArticleDOI
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
John H. Sampson,Gary E. Archer,Christoph Pedain,Eva Wembacher-Schröder,Manfred Westphal,Sandeep Kunwar,Michael A. Vogelbaum,April Coan,James E. Herndon,Raghu Raghavan,Martin Brady,David A. Reardon,Allan H. Friedman,Henry S. Friedman,M. Inmaculada Rodríguez-Ponce,Susan M. Chang,Stephan Mittermeyer,Davi Croteau,Raj K. Puri,James M. Markert,Michael D. Prados,Thomas C. Chen,Adam N. Mamelak,Timothy F. Cloughesy,John S. Yu,Kevin O. Lillehei,Joseph M. Piepmeier,Edward Pan,Frank D. Vrionis,H. Lee Moffitt,Jeffrey J. Olson,James P. Chandler,Nina Paleologos,Richard W. Byrne,Maciej S. Lesniak,Jon D. Weingart,Peter McL. Black,Tom Mikkelsen,Joon H. Uhm,Richard D. Bucholz,Lauren E. Abrey,Theodore H. Schwartz,Jeffrey N. Bruce,Anthony L. Asher,Stephen B. Tatter,Gene Barnett,Antonio E. Chiocca,Johnny B. Delashaw,Kevin Judy,Sunil J. Patel,Bruce Frankel,Frederick F. Lang,Pamela New,Karen Fink,Randy L. Jensen,Mark E. Shaffrey,Lynne P. Taylor,Warren Boling,Behnam Badie,Abhijit Guha,Vivek Mehta,Mark G. Hamilton,David D. Eisenstat,Farhad Pirouzmand,David R. Macdonald,Rolando F. Del Maestro,Daryl R. Fourney,Maximilian Mehdorn,Roland Goldbrunner,Gabriele Schackert,Andreas Unterberg,Zvi Ram,Zvi R. Cohen,Zvi H. Rappaport,Jan Jacob Mooij,John G. Wolbers,Peter C. Warnke,Varnavas Papanastassiou +77 more
TL;DR: Routine use of software algorithms and alternative catheter designs and infusion parameters may improve the efficacy of drugs delivered by CED, which may be severely constrained by ineffective delivery in many patients.